Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
Pregabalin probably leads to higher treatment withdrawal due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors leads to higher gastrointestinal adverse effects: diarrhoea compared with placebo (high certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: increase in blood pressure compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at increased risk of VTE in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 3, Safety of the intervention over 3 months: systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects, 20 placebo participants reported 20; 4 grade 3 events; 2 discontinued. Ketorolac…
2 studies
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 5, Safety of the intervention up to 3 months: 'All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was…
1 study
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 2, Safety of the intervention at 5 to 12 months: 'Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d (Nagao), and caused adverse effects of varying severity in 9% of…
3 studies
GRADE not reported
Gastrointestinal adverse events · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: gastrointestinal complaints compared with placebo (very low certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 1, Safety of the intervention at 4 to 12 months: '3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic…
4 studies
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Proportion with adverse effects of treatment · adults with subacute and chronic cough
Inhaled corticosteroids (ICS) showed no clear difference in proportion with adverse effects of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
Mixed action antidepressant showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
It is very uncertain whether anticonvulsants and mood stabilisers changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
Buspirone showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
N‐acetylcysteine showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
1 finding from 1 review